Alphatec Holdings, Inc. (“Alphatec” or the “Company”)
(Nasdaq:ATEC), a provider of innovative spine surgery solutions
with a mission to improve patient lives through the relentless
pursuit of superior outcomes, today announced financial results for
fourth quarter and full year ended December 31, 2017, and provided
guidance for 2018.
2017 Financial Highlights
|
Quarter Ended December
31, 2017 |
|
Year Ended December 31,
2017 |
|
|
|
|
Total
revenue |
$ 26.3 million |
|
$101.7 million |
U.S.
commercial revenue |
$ 20.9 million |
|
$ 86.9 million |
U.S.
gross margin |
69.9% |
|
69.8% |
Operating expenses |
$ 18.9 million |
|
$ 71.3 million |
Non-GAAP operating expenses |
$ 16.3 million |
|
$ 66.0 million |
Loss
from operations |
$(3.6) million |
|
$ (9.0) million |
Non-GAAP Adjusted EBITDA |
$ 1.0 million |
|
$ 3.8 million |
Cash
burn |
Less than $0.1 million |
|
$ 21.5 million |
|
|
|
|
“We closed 2017 with solid
momentum, and on excellent footing to continue to drive ATEC’s
advancement into an innovative, growth organization,” said Terry
Rich, President and Chief Operating Officer. “Throughout the year,
we demonstrated great progress with the transition of our sales
channel and aggressively managed expenses and cash. We have
an exceptionally strong understanding of what it will take to
achieve our vision and the strongest team in spine to accomplish
it.”
Comparison of Financial Results for the
Fourth Quarter 2017 to Third Quarter 2017
Following is a table, comparing key fourth
quarter 2017 results to third quarter 2017 results. At this
time, the Company believes that sequential results are the best
indicators of performance. These are the comparisons management
uses in its own evaluation of continuing operating performance
given the re-focus of the Company’s strategy under a new leadership
team.
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Change |
|
December 31, 2017 |
|
September 30, 2017 |
|
$000's |
|
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
U.S. commercial
revenue |
$ |
20,949 |
|
|
$ |
20,662 |
|
|
$ |
287 |
|
|
1.4 |
% |
U.S gross profit |
|
14,639 |
|
|
|
14,280 |
|
|
|
359 |
|
|
2.5 |
% |
U.S. gross margin |
|
69.9 |
% |
|
|
69.1 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
Operating Expenses |
|
|
|
|
|
|
|
Research
and development |
$ |
1,437 |
|
|
$ |
1,044 |
|
|
$ |
393 |
|
|
37.6 |
% |
Sales and
marketing |
|
9,742 |
|
|
|
10,015 |
|
|
|
(273 |
) |
|
(2.8 |
%) |
General
and administrative |
|
7,243 |
|
|
|
4,403 |
|
|
|
2,840 |
|
|
64.5 |
% |
Amortization of intangible assets |
|
172 |
|
|
|
172 |
|
|
|
- |
|
|
|
Restructuring expenses |
|
308 |
|
|
|
139 |
|
|
|
169 |
|
|
121.6 |
% |
Gain on
sale of assets |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
Total
operating expenses |
$ |
18,902 |
|
|
$ |
15,773 |
|
|
$ |
3,129 |
|
|
19.8 |
% |
|
|
|
|
|
|
|
|
Operating loss |
$ |
(3,608 |
) |
|
$ |
(1,261 |
) |
|
$ |
(2,347 |
) |
|
(186.1 |
%) |
|
|
|
|
|
|
|
|
Gain on change in
warrant fair value |
$ |
12,044 |
|
|
$ |
- |
|
|
$ |
12,044 |
|
|
NM |
|
|
|
|
|
|
|
|
Gain (loss) from
continuing operations |
$ |
6,589 |
|
|
$ |
(3,076 |
) |
|
$ |
9,665 |
|
|
314.2 |
% |
|
|
|
|
|
|
|
|
Non-GAAP Adjusted
EBITDA |
$ |
958 |
|
|
$ |
1,126 |
|
|
$ |
(168 |
) |
|
(14.9 |
%) |
|
|
|
|
|
|
|
|
U.S. commercial revenue for the fourth quarter
of 2017 was $20.9 million, up $0.2 million compared to $20.7
million in the third quarter of 2017. While U.S. commercial
revenue was essentially flat on a sequential basis, the percentage
of revenue generated by dedicated agents and distributors increased
to 40% up from approximately 30% in the third quarter of 2017.
Revenue growth generated by the dedicated sales channel has begun
to offset the revenue impacts associated with transitioning or
discontinuing non-strategic distributor relationships.
U.S. gross profit and gross margin for the
fourth quarter of 2017 were $14.6 million and 69.9%, respectively,
compared to $14.3 million and 69.1%, respectively, for the third
quarter of 2017. U.S. gross margin has stabilized as the Company
continues to optimize its supply chain.
Total operating expenses for the fourth quarter
of 2017 were $18.9 million, reflecting an increase of $3.1 million
compared to $15.8 million in the third quarter of 2017. On a
non-GAAP basis, excluding restructuring charges and stock-based
compensation, total operating expenses in the fourth quarter
increased from $15.2 million to $16.3 million, reflecting increased
investments in product development and leadership.
GAAP loss from continuing operations for the
fourth quarter of 2017 was $3.6 million, compared to a loss of $1.3
million for the third quarter of 2017, of which $1.9 million of the
additional loss was attributed to an increase in non-cash,
stock-based compensation.
Non-GAAP Adjusted EBITDA in the fourth quarter
of 2017 was $1.0 million, compared to $1.1 million in the third
quarter of 2017. For more detailed information, please refer
to the table, “Alphatec Holdings, Inc. Reconciliation of Non-GAAP
Financial Measures,” that follows.
Gain on change in fair value of warrants in the
fourth quarter of 2017 was $12.0 million, representing the change
in fair value of certain warrants to purchase common stock that
were temporarily classified as a liability on the consolidated
balance sheet, and subsequently reclassified as stockholders’
equity, in accordance with authoritative accounting guidance.
Current and long-term debt includes $32.4
million in term debt and $10.3 million outstanding under the
Company’s revolving credit facility at December 31, 2017. This
compares to $33.0 million in term debt and $9.2 million outstanding
under the Company’s revolving credit facility at September 30,
2017.
Cash and cash equivalents were $22.5 million at
December 31, 2017, compared to $15.4 million reported at September
30, 2017. During the fourth quarter of 2017, the Company
received additional equity investments of $3.7 million and
generated cash proceeds of $3.3 million from the exercise of
warrants.
Comparison of Financial Results for the
Twelve Months Ended December 31, 2017 and 2016
Revenue decreased on a year-over-year basis as a
result of the Company’s execution of its sales organization
transition and the impact of lost revenue related to the financial
and operational challenges the Company faced in 2016 prior to the
sale of its international business. The year-over-year
improvement in operating expenses is the result of a comprehensive
initiative to reduce costs and drive operational
efficiencies. For additional information, please reference
the following financial statement tables and the Company’s Annual
Report on Form 10-K to be filed with the Securities and Exchange
Commission on or about March 9, 2018.
2018 Financial Outlook
Alphatec expects total revenue in 2018 to
approximate $95.0 million, an increase in the U.S. commercial
revenue run rate reported for the second half of 2017.
Rich continued, “As the transition of our
distribution channel progresses, top-line visibility will continue
to be somewhat limited as we discontinue non-strategic
relationships and navigate the contracting process to execute each
transition. However, I am proud to say that we are beginning
to see our efforts reach fruition. As 2018 progresses, we
expect that sales from the dedicated portion of our channel will
continue to offset the negative revenue impacts associated with
transitioning or discontinuing non-strategic distributor
relationships.”
Investor Conference Call
Alphatec will hold a conference today at 2:30
p.m. PT / 5:30 p.m. ET to discuss the results. The dial-in numbers
are (877) 556-5251 for domestic callers and (720) 545-0036 for
international callers. The conference ID number is 7887979. A live
webcast of the conference call will be available online from the
investor relations page of the Company’s corporate website at
www.atecspine.com.
About Alphatec Holdings,
Inc.
Alphatec Holdings, Inc., through its wholly
owned subsidiary Alphatec Spine, Inc., is a medical device company
that designs, develops, and markets spinal fusion technology
products and solutions for the treatment of spinal disorders
associated with disease and degeneration, congenital deformities,
and trauma. The Company's mission is to improve lives by providing
innovative spine surgery solutions through the relentless pursuit
of superior outcomes. The Company markets its products in the U.S.
via independent sales agents and a direct sales force.
Additional information can be found at
www.atecspine.com.
Forward Looking Statements
This press release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995 that involve risks and uncertainty. Such
statements are based on management's current expectations and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. The Company cautions investors that
there can be no assurance that actual results or business
conditions will not differ materially from those projected or
suggested in such forward-looking statements as a result of various
factors. Forward-looking statements include the references to the
Company’s strategy in significantly repositioning the Alphatec
brand and turning the Company into a growth organization. The
important factors that could cause actual operating results to
differ significantly from those expressed or implied by such
forward-looking statements include, but are not limited to:
the uncertainty of success in developing new products or products
currently in the Company’s pipeline; the uncertainties in the
Company’s ability to execute upon its strategic operating plan; the
uncertainties regarding the ability to successfully license or
acquire new products, and the commercial success of such products;
failure to achieve acceptance of the Company’s products by the
surgeon community, including Battalion and Arsenal Deformity;
failure to obtain FDA or other regulatory clearance or approval for
new products, or unexpected or prolonged delays in the process;
continuation of favorable third party reimbursement for procedures
performed using the Company’s products; unanticipated expenses or
liabilities or other adverse events affecting cash flow or the
Company’s ability to successfully control its costs or achieve
profitability; uncertainty of additional funding; the Company’s
ability to compete with other competing products and with emerging
new technologies; product liability exposure; an unsuccessful
outcome in any litigation in which the Company is a defendant;
patent infringement claims; claims related to the Company’s
intellectual property and the Company’s ability to meet its
financial obligations under its credit agreements and the Orthotec
settlement agreement. The words “believe,” “will,” “should,”
“expect,” “intend,” “estimate” and “anticipate,” variations of such
words and similar expressions identify forward-looking statements,
but their absence does not mean that a statement is not a
forward-looking statement. A further list and description of
these and other factors, risks and uncertainties can be found in
the Company's most recent annual report, and any subsequent
quarterly and current reports, filed with the Securities and
Exchange Commission. Alphatec disclaims any intention or obligation
to update or revise any forward-looking statements, whether as a
result of new information, future events, or otherwise, unless
required by law.
Investor/Media Contact:
Lee Roth / Emma PoalilloThe Ruth Group(646)
536-7000alphatec@theruthgroup.com
Company Contact:
Jeff BlackExecutive Vice President and Chief
Financial OfficerAlphatec Holdings, Inc.ir@atecspine.com
|
ALPHATEC HOLDINGS, INC. |
CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS |
(in thousands, except
per share amounts) |
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Twelve Months Ended |
|
December
31, |
|
|
December
31, |
|
|
2017 |
|
|
|
2016 |
|
|
|
|
2017 |
|
|
|
2016 |
|
|
|
|
|
|
|
|
|
|
Revenues |
$ |
26,283 |
|
|
$ |
27,090 |
|
|
|
$ |
101,739 |
|
|
$ |
120,248 |
|
Cost of revenues |
|
10,989 |
|
|
|
12,463 |
|
|
|
|
39,406 |
|
|
|
44,114 |
|
Gross profit |
|
15,294 |
|
|
|
14,627 |
|
|
|
|
62,333 |
|
|
|
76,134 |
|
|
|
|
|
|
|
|
|
|
Operating
expenses: |
|
|
|
|
|
|
|
|
Research
and development |
|
1,437 |
|
|
|
2,449 |
|
|
|
|
4,920 |
|
|
|
9,248 |
|
Sales and
marketing |
|
9,742 |
|
|
|
11,464 |
|
|
|
|
41,158 |
|
|
|
50,962 |
|
General
and administrative |
|
7,243 |
|
|
|
6,923 |
|
|
|
|
23,220 |
|
|
|
26,339 |
|
Amortization of intangible assets |
|
172 |
|
|
|
341 |
|
|
|
|
688 |
|
|
|
934 |
|
Restructuring expenses |
|
308 |
|
|
|
514 |
|
|
|
|
2,206 |
|
|
|
2,292 |
|
Goodwill
and intangible asset impairment |
|
- |
|
|
|
|
|
|
- |
|
|
|
1,736 |
|
Gain on
sale of assets |
|
- |
|
|
|
- |
|
|
|
|
(856 |
) |
|
|
- |
|
Total
operating expenses |
|
18,902 |
|
|
|
21,691 |
|
|
|
|
71,336 |
|
|
|
91,511 |
|
Operating loss |
|
(3,608 |
) |
|
|
(7,064 |
) |
|
|
|
(9,003 |
) |
|
|
(15,377 |
) |
Other income
(expense) |
|
|
|
|
|
|
|
|
Interest
and other expense, net |
|
(1,938 |
) |
|
|
7,476 |
|
|
|
|
(7,615 |
) |
|
|
(5,393 |
) |
Loss on
debt extinguishment |
|
- |
|
|
|
(9,478 |
) |
|
|
|
- |
|
|
|
(9,478 |
) |
Gain on
change in fair value of warrants |
|
12,044 |
|
|
|
(687 |
) |
|
|
|
12,044 |
|
|
|
(687 |
) |
Total
other income (expense), net |
|
10,106 |
|
|
|
(2,689 |
) |
|
|
|
4,429 |
|
|
|
(15,558 |
) |
Loss from continuing
operations before taxes |
|
6,498 |
|
|
|
(9,753 |
) |
|
|
|
(4,574 |
) |
|
|
(30,935 |
) |
Income
tax provision |
|
(91 |
) |
|
|
328 |
|
|
|
|
(34 |
) |
|
|
(4,634 |
) |
Gain (loss) from
continuing operations |
|
6,589 |
|
|
|
(10,081 |
) |
|
|
|
(4,540 |
) |
|
|
(26,301 |
) |
Gain (loss) from
discontinued operations |
|
2,466 |
|
|
|
5,727 |
|
|
|
|
2,246 |
|
|
|
(3,624 |
) |
Net loss |
$ |
9,055 |
|
|
$ |
(4,354 |
) |
|
|
$ |
(2,294 |
) |
|
$ |
(29,925 |
) |
|
|
|
|
|
|
|
|
|
Net loss per share
continuing operations |
$ |
0.39 |
|
|
$ |
(1.18 |
) |
|
|
$ |
(0.36 |
) |
|
$ |
(3.06 |
) |
Net loss per share
discontinued operations |
|
0.14 |
|
|
|
0.67 |
|
|
|
|
0.18 |
|
|
|
(0.42 |
) |
Net loss per
share - basic and diluted |
$ |
0.53 |
|
|
$ |
(0.51 |
) |
|
|
$ |
(0.18 |
) |
|
$ |
(3.49 |
) |
|
|
|
|
|
|
|
|
|
Weighted-average shares
- basic and diluted |
|
17,062 |
|
|
|
8,560 |
|
|
|
|
12,788 |
|
|
|
8,582 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based
compensation included in: |
|
|
|
|
|
|
|
|
Cost of revenue |
|
28 |
|
|
|
20 |
|
|
|
|
40 |
|
|
|
36 |
|
Research and
development |
|
150 |
|
|
|
375 |
|
|
|
|
207 |
|
|
|
438 |
|
Sales and
marketing |
|
245 |
|
|
|
140 |
|
|
|
|
480 |
|
|
|
258 |
|
General and
adminstrative |
|
2,188 |
|
|
|
142 |
|
|
|
|
3,255 |
|
|
|
894 |
|
|
$ |
2,611 |
|
|
$ |
677 |
|
|
|
$ |
3,982 |
|
|
$ |
1,626 |
|
|
|
|
|
|
|
|
|
|
|
ALPHATEC HOLDINGS, INC. |
CONDENSED CONSOLIDATED BALANCE
SHEETS |
(in
thousands) |
|
|
|
|
|
December 31, |
|
December 31, |
|
|
2017 |
|
|
|
2016 |
|
|
|
|
|
ASSETS |
Current assets: |
|
|
|
Cash and
cash equivalents |
$ |
22,466 |
|
|
$ |
19,593 |
|
Accounts
receivable, net |
|
14,822 |
|
|
|
18,512 |
|
Inventories, net |
|
27,292 |
|
|
|
30,093 |
|
Prepaid
expenses and other current assets |
|
1,767 |
|
|
|
4,262 |
|
Current
assets of discontinued operations |
|
131 |
|
|
|
364 |
|
Total current
assets |
|
66,478 |
|
|
|
72,824 |
|
|
|
|
|
Property and equipment,
net |
|
12,670 |
|
|
|
15,076 |
|
Intangibles, net |
|
5,248 |
|
|
|
5,711 |
|
Other assets |
|
208 |
|
|
|
516 |
|
Noncurrent assets of
discontinued operations |
|
56 |
|
|
|
61 |
|
Total assets |
$ |
84,660 |
|
|
$ |
94,188 |
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS'
DEFICIT |
Current
liabilities: |
|
|
|
Accounts
payable |
$ |
3,878 |
|
|
$ |
8,701 |
|
Accrued
expenses |
|
22,246 |
|
|
|
27,589 |
|
Current
portion of long-term debt |
|
3,306 |
|
|
|
3,113 |
|
Current
liabilities of discontinued operations |
|
312 |
|
|
|
732 |
|
Total current
liabilities |
|
29,742 |
|
|
|
40,135 |
|
|
|
|
|
Total
long term liabilities |
|
57,973 |
|
|
|
71,954 |
|
Redeemable preferred stock |
|
23,603 |
|
|
|
23,603 |
|
Stockholders' deficit |
|
(26,658 |
) |
|
|
(41,504 |
) |
Non-controlling interest |
|
|
|
0 |
|
Total liabilities and
stockholders' deficit |
$ |
84,660 |
|
|
$ |
94,188 |
|
|
|
|
|
|
ALPHATEC HOLDINGS, INC. |
RECONCILIATION OF NON-GAAP FINANCIAL
MEASURES |
(in thousands -
unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Three Months Ended |
|
|
Twelve Months Ended |
|
|
September 30, |
|
December 31, |
|
|
December 31, |
|
|
|
2017 |
|
|
|
2017 |
|
|
|
2016 |
|
|
|
|
2017 |
|
|
|
2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss, as
reported |
|
$ |
(1,261 |
) |
|
$ |
(3,608 |
) |
|
$ |
(7,064 |
) |
|
|
$ |
(9,003 |
) |
|
$ |
(15,377 |
) |
Add back: |
|
|
|
|
|
|
|
|
|
|
|
Depreciation |
|
|
1,564 |
|
|
|
1,711 |
|
|
|
1,735 |
|
|
|
|
6,545 |
|
|
|
7,387 |
|
Amortization of intangible assets |
|
|
234 |
|
|
|
234 |
|
|
|
693 |
|
|
|
|
936 |
|
|
|
1,608 |
|
Total EBITDA |
|
|
537 |
|
|
|
(1,663 |
) |
|
|
(4,636 |
) |
|
|
|
(1,522 |
) |
|
|
(6,382 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
Add back significant
items: |
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation |
|
|
450 |
|
|
|
2,313 |
|
|
|
1,931 |
|
|
|
|
3,982 |
|
|
|
3,441 |
|
Restructuring and other charges |
|
|
139 |
|
|
|
308 |
|
|
|
514 |
|
|
|
|
2,206 |
|
|
|
2,292 |
|
Goodwill
and intangible asset impairment |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
- |
|
|
|
1,736 |
|
Gain on
sale of assets |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
(856 |
) |
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA |
|
$ |
1,126 |
|
|
$ |
958 |
|
|
$ |
(2,191 |
) |
|
|
$ |
3,810 |
|
|
$ |
1,087 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Three Months Ended |
|
|
Twelve Months Ended |
|
|
September 30, |
|
December 31, |
|
|
December 31, |
|
|
|
2017 |
|
|
|
2017 |
|
|
|
2016 |
|
|
|
|
2017 |
|
|
|
2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses, as
reported |
|
$ |
15,773 |
|
|
$ |
18,902 |
|
|
$ |
21,691 |
|
|
|
$ |
71,336 |
|
|
$ |
91,511 |
|
Less: |
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation |
|
|
(450 |
) |
|
|
(2,313 |
) |
|
|
(1,931 |
) |
|
|
|
(3,982 |
) |
|
|
(3,441 |
) |
Restructuring and other charges |
|
|
(139 |
) |
|
|
(308 |
) |
|
|
(514 |
) |
|
|
|
(2,206 |
) |
|
|
(2,292 |
) |
Goodwill
and intangible asset impairment |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
- |
|
|
|
(1,736 |
) |
Gain on
sale of assets |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
856 |
|
|
|
- |
|
Non-GAAP operating
expenses |
|
$ |
15,184 |
|
|
$ |
16,281 |
|
|
$ |
19,246 |
|
|
|
$ |
66,004 |
|
|
$ |
84,042 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ALPHATEC HOLDINGS, INC. |
RECONCILIATION OF GEOGRAPHIC SEGMENT REVENUES
AND GROSS PROFIT |
(in thousands, except percentages -
unaudited) |
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Three Months Ended |
|
Twelve Months Ended |
|
September 30, |
|
December 31, |
|
December 31, |
|
|
2017 |
|
|
|
2017 |
|
|
|
2016 |
|
|
|
2017 |
|
|
|
2016 |
|
|
|
|
|
|
|
|
|
|
|
Revenues by source |
|
|
|
|
|
|
|
|
|
U.S. commercial
revenue |
$ |
20,662 |
|
|
$ |
20,949 |
|
|
$ |
24,473 |
|
|
$ |
86,925 |
|
|
$ |
106,918 |
|
Other |
|
2,437 |
|
|
|
5,334 |
|
|
|
2,617 |
|
|
|
14,814 |
|
|
|
13,330 |
|
Total revenues |
$ |
23,099 |
|
|
$ |
26,283 |
|
|
$ |
27,090 |
|
|
$ |
101,739 |
|
|
$ |
120,248 |
|
|
|
|
|
|
|
|
|
|
|
Gross profit by
source |
|
|
|
|
|
|
|
|
|
U.S. |
$ |
14,280 |
|
|
$ |
14,639 |
|
|
$ |
15,002 |
|
|
$ |
60,709 |
|
|
$ |
71,432 |
|
Other |
|
232 |
|
|
|
655 |
|
|
|
(375 |
) |
|
|
1,624 |
|
|
|
4,702 |
|
Total gross profit |
$ |
14,512 |
|
|
$ |
15,294 |
|
|
$ |
14,627 |
|
|
$ |
62,333 |
|
|
$ |
76,134 |
|
|
|
|
|
|
|
|
|
|
|
Gross profit margin by
source |
|
|
|
|
|
|
|
|
|
U.S. |
|
69.1 |
% |
|
|
69.9 |
% |
|
|
61.3 |
% |
|
|
69.8 |
% |
|
|
66.8 |
% |
Other |
|
9.5 |
% |
|
|
12.3 |
% |
|
|
(14.3 |
%) |
|
|
11.0 |
% |
|
|
35.3 |
% |
Total gross profit
margin |
|
62.8 |
% |
|
|
58.2 |
% |
|
|
54.0 |
% |
|
|
61.3 |
% |
|
|
63.3 |
% |
|
|
|
|
|
|
|
|
|
|
Alphatec (NASDAQ:ATEC)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Alphatec (NASDAQ:ATEC)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024